Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2026-05-22 @ 8:09 AM
Study NCT ID:
NCT05676203
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-02-17
First Post:
2022-12-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
Sponsor:
Jena University Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | View |